“Vertex Pharmaceuticals (NASDAQ: VRTX), as the cystic fibrosis leader once again received some great news from across the pond, which it then shared with its investors. The European Union has officially given Orkambi, its new cystic fibrosis medicine, the green light for marketing authorization in
“Alnylam Pharmaceuticals Injects Some Bad News Into Its Earnings Report Injection-site reactions cause three patients to drop out of a clinical trial for revusiran.”